In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Changes in novel biomarkers of hypertrophy and fibrosis are better predictors of cardiovascular admission than those of cardiac myocyte stretch in patients with chronic heart failure

Session Poster session 1 Saturday 08:30 -17:30

Speaker Susan Piper

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P238

Authors : S Piper (London,GB), D Hipperson (London,GB), J Decourcey (London,GB), R Sherwood (London,GB), G Amin-Youssef (London,GB), A Shah (London,GB), TA Mcdonagh (London,GB)


S Piper1 , D Hipperson2 , J Decourcey2 , R Sherwood2 , G Amin-Youssef2 , A Shah1 , TA Mcdonagh1 , 1King's College London - London - United Kingdom , 2King's College Hospital - London - United Kingdom ,

European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 48

Background: The B-type natriuretic peptides, BNP and NTproBNP, are established markers of cardiac myocyte stretch advocated for diagnostic and prognostic use in heart failure patients. The evidence for serial monitoring to predict decompensation in heart failure has, however, been mixed. We examined serial concentrations of four novel biomarkers to ascertain superiority over NTproBNP in predicting cardiovascular admission; sST2 and Galectin-3, both markers of hypertrophy/fibrosis, and Apelin and Mid-regional pro-adrenomedullin (MRproADM) both markers of cardiac myocyte stretch.

Methods: We prospectively studied 50 patients with stable CHF due to LV systolic dysfunction. All patients were on optimum doses of prognostically indicated medications and in NYHA Class I-III. Mean age was 67.3 years (SD 11.568), 82% were male and 48% had IHD. Mean LVEF was 30.7%. Patients were followed for a period of 6 months with samples drawn at baseline, 1 month, 3 months and 6 months.

Results: On ROC analysis, AUC for % change in the respective biomarkers and CV admission was 0.803 (p = 0.012) for Galectin-3, 0.734 (p = 0.052) for sST2, 0.571 (p = 0.553) for Apelin, 0.506 (p = 0.962) for MRproADM and 0.571 (p = 0.553) for NTproBNP. Comparable results were found for absolute changes in biomarker concentrations with AUC of 0.807 (p = 0.011), 0.734 (p = 0.052), 0.417 P = 0.490), 0.546 (p = 0.700) and 0.579 (p = 0.511) respectively.

Conclusion: Markers of hypertrophy/fibrosis, sST2 and Galectin-3, are better predictors of CV admission than either NTproBNP or other novel markers of cardiac myocyte stretch. This may reflect longer-term adverse pathophysiological changes associated with hypertrophy and fibrosis compared with those of stretch. Further studies are required to corroborate these findings.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are